Effects of alendronate with or without hormone replacement therapy on bone mineral density in postmenopausal osteoporotic women

Introduction: Osteoporosis is an important problem in postmenopausal women. The use of best treatment is crucial to attainin g appropriate therapeutic and prophylactic outcomes. Combination therapy versus single therapy may develop better results. This study was performed to determine the effects of alendronate alone versus plus hormone replacement therapy (HRT) on bone mineral density (BMD) in Iranian postmenopausal osteoporotic women women. Materials and Methods: In this randomized clinical trial ۲۰۰ consecutive postmenopausal osteoporotic women since ۲۰۱۸ to ۲۰۲۰ were enrolled and randomly assigned to receive either alendronate ۷۰ mg alone or plus HRT ۰.۶۲۵ mg CEE and ۲.۵ mg medroxyprogesterone acetate. The improvement in BMD, hot flash, vaginal dryness, dyspareunia, and mood disorders was assessed after ۱۲ months and compared across the groups. SPSS software by KolmogorovKolmogorov-Smirnov, Chi Chi-Square, and Mann Mann-WhitneyWhitney-U tests tests. Results: Complete improvement in BMD was seen in ۲۰ and ۴۷ percent in single and combination groups, respectively with statistically significant difference (P=۰.۰۰۱). According to results, the i mprovements in hot flashes (P=۰.۰۴۸), vaginal dryness (P=۰.۰۰۱), dyspareunia (P=۰.۰۰۲), and mood disorders (P=۰.۰۰۱) in women were better in combination group group. Conclusion: The addition of HRT to alendronate can increase the therapeutic effects on BMD and other symptoms in postmenopausal osteoporotic women and its use is recommended recommended.